Citadel Advisors’s Atea Pharmaceuticals AVIR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-21,992
| Closed | -$65.8K | – | 5838 |
|
|
2025
Q1 | $65.8K | Sell |
21,992
-196,796
| -90% | -$588K | ﹤0.01% | 5295 |
|
|
2024
Q4 | $733K | Sell |
218,788
-376,461
| -63% | -$1.26M | ﹤0.01% | 3582 |
|
|
2024
Q3 | $1.99M | Buy |
595,249
+69,646
| +13% | +$233K | ﹤0.01% | 2504 |
|
|
2024
Q2 | $1.74M | Buy |
525,603
+329,603
| +168% | +$1.09M | ﹤0.01% | 2569 |
|
|
2024
Q1 | $792K | Buy |
196,000
+22,986
| +13% | +$92.9K | ﹤0.01% | 3435 |
|
|
2023
Q4 | $528K | Sell |
173,014
-411,674
| -70% | -$1.26M | ﹤0.01% | 3678 |
|
|
2023
Q3 | $1.75M | Sell |
584,688
-897,095
| -61% | -$2.69M | ﹤0.01% | 2515 |
|
|
2023
Q2 | $5.54M | Sell |
1,481,783
-99,925
| -6% | -$374K | ﹤0.01% | 1643 |
|
|
2023
Q1 | $5.3M | Buy |
1,581,708
+975,523
| +161% | +$3.27M | ﹤0.01% | 1765 |
|
|
2022
Q4 | $2.92M | Buy |
606,185
+313,381
| +107% | +$1.51M | ﹤0.01% | 2240 |
|
|
2022
Q3 | $1.67M | Buy |
292,804
+33,750
| +13% | +$192K | ﹤0.01% | 2920 |
|
|
2022
Q2 | $1.84M | Sell |
259,054
-1,295,171
| -83% | -$9.19M | ﹤0.01% | 2814 |
|
|
2022
Q1 | $11.2M | Sell |
1,554,225
-114,707
| -7% | -$828K | ﹤0.01% | 1309 |
|
|
2021
Q4 | $14.9M | Buy |
1,668,932
+1,569,450
| +1,578% | +$14M | ﹤0.01% | 1138 |
|
|
2021
Q3 | $3.49M | Buy |
99,482
+42,001
| +73% | +$1.47M | ﹤0.01% | 2393 |
|
|
2021
Q2 | $1.24M | Buy |
57,481
+53,467
| +1,332% | +$1.15M | ﹤0.01% | 3740 |
|
|
2021
Q1 | $248K | Sell |
4,014
-164,191
| -98% | -$10.1M | ﹤0.01% | 5211 |
|
|
2020
Q4 | $7.03M | Buy |
+168,205
| New | +$7.03M | ﹤0.01% | 1489 |
|